Brokerages expect that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will post ($0.46) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.47). Corvus Pharmaceuticals posted earnings of ($0.62) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.8%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.02) to ($1.94). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.79) per share, with EPS estimates ranging from ($1.88) to ($1.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, August 2nd. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.24.

Several equities research analysts have commented on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Thursday, June 14th. ValuEngine raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 7th. Jefferies Financial Group started coverage on shares of Corvus Pharmaceuticals in a report on Tuesday, June 5th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, BidaskClub raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $13.67.

Several hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Corvus Pharmaceuticals by 16.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 156,471 shares of the company’s stock worth $1,718,000 after acquiring an additional 22,035 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Corvus Pharmaceuticals by 51.9% during the 2nd quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock worth $12,290,000 after acquiring an additional 382,389 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Corvus Pharmaceuticals by 48.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after acquiring an additional 8,400 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Corvus Pharmaceuticals by 35.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after acquiring an additional 9,782 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth about $147,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:CRVS traded down $0.05 during mid-day trading on Friday, hitting $9.37. The company’s stock had a trading volume of 31,726 shares, compared to its average volume of 70,484. Corvus Pharmaceuticals has a 1 year low of $7.42 and a 1 year high of $17.64.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Further Reading: What does EPS mean?

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.